FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      
           
This page is updated frequently with new Vaccine-related patent applications. Subscribe to the Vaccine RSS feed to automatically get the update: related Vaccine RSS feeds. RSS updates for this page: Vaccine RSS RSS


Date/App# patent app List of recent Vaccine-related patents
08/28/14
20140242669
 Production of infectious rna viruses in yeast patent thumbnailnew patent Production of infectious rna viruses in yeast
The method described herein provides a novel platform utilizing yeast as a biological non-host system to express and assemble whole viruses for use as attenuated or killed vaccines.. .
08/28/14
20140242115
 Inactivating pathogens with oxidizing agents for vaccine production patent thumbnailnew patent Inactivating pathogens with oxidizing agents for vaccine production
The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites.
08/28/14
20140242114
 Cdna construct of salmonidae alphavirus patent thumbnailnew patent Cdna construct of salmonidae alphavirus
The invention concerns recombinant dna's comprising cdna of genomic rna of a salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant dnas are useful for obtaining expression vectors, producing recombinant salmonidae alphavirus, and for obtaining vaccines..
08/28/14
20140242113
 Liquid vaccine preparations patent thumbnailnew patent Liquid vaccine preparations
This document provides methods and materials involved in making and using liquid vaccine preparations for oral administration. For example, methods and materials for making and using liquid vaccine preparations for oral administration that include a lyophilized or dried vaccine component (e.g., a lyophilized pathogenic agent such as a lyophilized rotavirus preparation) and a liquid edible oil composition (e.g., a liquid edible oil composition containing one or more medium chain triglycerides) are provided.
08/28/14
20140242106
 Staphylococcus aureus proteins and nucleic acids patent thumbnailnew patent Staphylococcus aureus proteins and nucleic acids
The invention provides proteins from staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics..
08/28/14
20140242105
 Vaccines for chlamydia patent thumbnailnew patent Vaccines for chlamydia
The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus chlamydia. In particular, the present invention relates to isolated b- and t-cell epitopes derived from the major outer membrane protein of chlamydia psittaci which can be used against an infection with a species of the genus chlamydia.
08/28/14
20140242104
 Self-assembling peptide nanoparticles as vaccines against infection with norovirus patent thumbnailnew patent Self-assembling peptide nanoparticles as vaccines against infection with norovirus
Self-assembling peptide nanoparticles (sapn) incorporating t-cell epitopes and displaying the p domain of the norovirus protein vp1 are described. The nanoparticles of the invention consist of aggregates of a continuous peptide chain comprising two coiled coil oligomerization domains connected by a linker segment wherein one or both oligomerization domains incorporate t-cell epitopes within their peptide sequence.
08/28/14
20140242102
 Influenza hemagglutinin and neuraminidase variants patent thumbnailnew patent Influenza hemagglutinin and neuraminidase variants
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.. .
08/21/14
20140235836
 Immunologic constructs and methods patent thumbnailImmunologic constructs and methods
The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity and/or improve folding of the protein..
08/21/14
20140234373
 Methods of promoting immune tolerance patent thumbnailMethods of promoting immune tolerance
Compositions including a polynucleotide combined with a vehicle and methods of their use to induce a suppressive immune response are provided. In some embodiments the compositions induce an increase in expression of indoleamine 2,3 dioxygenase (ido) enzyme activity in cells.
08/21/14
20140234372
Novel vlps derived from cells that do not express a viral matrix or core protein
The present invention discloses novel influenza virus-like particles (vlps) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins.
08/21/14
20140234364
Total synthesis and immunological evaluation of saccharide moieties of the lipopolysaccharide from neisseria meningitidis
The present invention relates to the total chemical synthesis of the monosaccharide 35# (r′═h), the disaccharide 36# (r′≠h; r″═h), the trisaccharide 37# (r′≠h; r″≠h; r′″≠h) and the tetrasaccharide 1# (r′≠h; r″≠h; r′″≠h) of the following general formula wherein r represents —y—nh2y represents a linker r′ is h or r″ is h or r′″ is h or of the lipopolysaccharide from neisseria meningitidis, as well as to the trisaccharide 37# and the tetrasaccharide 1#, to vaccines containing at least one of the saccharides 1#, 35#, 36#, and 37# and to the use of such vaccine for immunization against diseases caused by infection with bacteria containing the tetrasaccharide α-glcnac-(1→2)-α-hep-(1→3)-α-hep-(1→5)-α-kdo or the trisaccharide α-hep-(1→3)-α-hep-(1→5)-α-kdo or α-glcnac-(1→2)-α-hep-(1→3)-α-hep, especially for immunization against meningitis, septicaemia, pneumonia and nasopharyngitis caused by neisseria meningitidis.. .
08/21/14
20140234360
Influenza vaccine
Disclosed are immunogenic conjugates having the general formula: ha2-xxx-pr, where ha2 is the influenza ha2 fusion peptide or a portion thereof, xxx is a linker and pr is the carrier. Methods of producing an immune response in a subject using the disclosed immunogenic conjugates, as well as methods of treating, ameliorating or preventing influenza infection, are also disclosed..
08/21/14
20140234359
Plant viral vaccines and therapeutics
The invention relates to methods and related products for preventing and treating disease, based on the use of plant viral vaccines and plant viral defense strategies. The methods also involve the identification of appropriate therapeutic strategies for diseases such as cancers..
08/21/14
20140234358
Newcastle disease virus vectored avian vaccines
The present invention encompasses engineered newcastle disease virus (ndv) vaccines or compositions. The vaccine or composition may be a recombinant vaccine.
08/21/14
20140234356
Influenza antigen delivery vectors and constructs
The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans..
08/21/14
20140234355
Infectious clones of torque teno virus
The present invention is directed to novel nucleotide and amino acid sequences of torque teno virus (“ttv”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine ttv genotypes and isolates.
08/21/14
20140234354
Porcine parvovirus 5b, methods of use and vaccine
The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5b (ppv5b) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus..
08/21/14
20140234351
Cancer vaccines and vaccination methods
Compositions of multipeptide vaccines comprising at least seven tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from at least seven tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating gynecological and peritoneal cancers using such vaccines..
08/21/14
20140234350
Ovarian cancer vaccines and vaccination methods
Compositions of multipeptide vaccines including tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating ovarian cancers using such vaccines..
08/21/14
20140234349
Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
The present invention regards nanoparticles comprising a sterol and a component derived from quillaja saponaria molina selected from quillaja acid and quillaja saponin, which nanoparticles do not comprise a phospholipid. It also relates to a composition comprising the nanoparticles, and the use thereof as adjuvant, especially in vaccines, as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer.
08/21/14
20140234344
Anti-cd40 antibodies and uses thereof
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-cd40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-cd40 antibody or fragments thereof, including humanized antibodies..
08/21/14
20140234318
Tumor specific oligosaccharide epitopes and use thereof
The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal n-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer.
08/14/14
20140227786
Retroviral vector particles and methods for their generation and use
The present invention relates to methods of host cell transduction utilising ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of friend murine leukaemia virus, in particular the envelope encoded by molecular clone pvc-211 and the host cell may be engineered to recombinantly express the rec1 receptor.
08/14/14
20140227741
Biological systems for production of highest quality proteins
Vaccines and therapeutic proteins, including polyclonal and monoclonal antibodies, must be maximally pure and stable in their most active native form. This is a requirement for their maximal efficacy, specificity and stability as well as for precluding immune responses against erroneous or damaged moieties.
08/14/14
20140227314
Engineered type iv pilin of clostridium difficile
The present invention relates to engineered clostridium difficile type iv pilin (tfp) genes, type iv pilin proteins which can serve as a diagnostic marker for identification of patients infected with c. Difficile, and vaccines comprising type iv pilin proteins, antigenic fragments and variants thereof for therapeutic interventions..
08/14/14
20140227312
A1 moiety of cholera toxin a subunit as an adjuvant for mucosal and systemic vaccines
The present invention relates to cholera toxin cta1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant cta1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator..
08/14/14
20140227311
Method for removing immunosuppressive properties of hiv envelope glycoproteins
The present invention concerns a method for removal of immunosuppressive effects of envelope glycoproteins derived from human immunodeficiency virus, such as for vaccination purposes and for generation of neutralizing antibodies to hiv. The invention further concerns vaccines and antibodies obtainable by the method, as well as the use of such vaccines and antibodies..
08/14/14
20140227307
Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
Herpes simplex virus-2 (hsv-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against hsv-2.
08/14/14
20140227306
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
The present invention relates to use of multimeric multi-epitope peptide-based compositions for immunizing subjects against influenza by administering the compositions to the subject prior to or together with seasonal or pandemic influenza vaccines. The present invention also relates to compositions that include a multimeric multi-epitope polypeptide and a seasonal or pandemic preparation against influenza..
08/14/14
20140227304
Vaccines for preventing and treating alzheimer's disease
Disclosed herein are vaccines comprising an amyloid beta antigen and a nucleic acid encoding the amyloid beta antigen, or a variant thereof. T cell proliferation can be inhibited and itreg cells can be stimulated in the subject administered the vaccine.
08/14/14
20140227185
Glutathione-based drug delivery system
The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like dna vaccines, antisense oligonucleotides, ribozymes, catalytic dna (dnazymes) or rna molecules, sirnas or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (cns), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs.
08/07/14
20140221569
Decorated macromolecular scaffolds
The present invention relates to a method for preparing decorated macromolecular scaffolds. The method of the invention is useful for the generation of bioactive nanoparticles for use in clinical applications.
08/07/14
20140220675
Platform of dendritic cell (dc)-based vaccination
The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of dc1s generated in serum-supplemented cultures. The invention further discloses methods and systems using ifnγ and other ligands of the ifnγ receptor, in combination with ifnα (or other type i interferons), poly i:c, and other ifnα (and ifnβ) inducers to enhance the il-12-producing properties of dendritic cells.
08/07/14
20140220661
Live bacterial vaccines for prophylaxis or treatment of infection
A live bacterium, having a dna construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation.
08/07/14
20140220600
Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
08/07/14
20140220107
Truncated hiv envelope proteins (env), methods and compositions related thereto
The instant application provides methods and related compositions pertaining to novel hiv envelope proteins. In some embodiments, the invention relates to methods and compositions for the preparation, production, and administration of isolated novel hiv envelope nucleic acid and protein sequences suitable, for example, as vaccines against hiv..
08/07/14
20140220105
Tape preparation of wt1 peptide cancer vaccine for transdermal administration
(ii) a first cellular immunity induction promoter. The tape preparation can provides high efficacy..
08/07/14
20140220100
Vaccine composition for transdermal administration
The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) her2/neu e75 peptide and/or a modified her2/neu e75 peptide; and (ii) a first cellular immunity induction promoter.. .
08/07/14
20140220083
Cationic oil-in-water emulsions
This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles.
08/07/14
20140220079
Vaccine composition for mucosal administration
The present invention provides a cancer vaccine composition for mucosal administration comprising (i) a her2/neu e75 peptide and/or a modified her2/neu e75 peptide; and (ii) a first cellular immunity induction promoter.. .
08/07/14
20140220077
New modified live flavobacterium strains, stabilized vaccines comprising same, and methods of making and use thereof
The present invention provides attenuated f. Columnare strains that elicit an immune response in an animal, particularly a fish, against virulent f.
08/07/14
20140220076
Recombinant mistletoe lectin and use thereof as an adjuvant
The invention relates to vaccines that comprise antigens and an adjuvant, and to the use of the adjuvant, wherein the adjuvant is selected from a recombinant mistletoe lectin.. .
08/07/14
20140220075
Multi plasmid system for the production of influenza virus
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided..
08/07/14
20140220059
Wt1 peptide cancer vaccine composition for mucosal administration
The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a wt1 peptide and/or a modified wt1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject..
08/07/14
20140220057
Wt1 peptide cancer vaccine composition for transdermal administration
The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a wt1 peptide and/or a modified wt1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.. .
08/07/14
20140220055
Wt1 peptide cancer vaccine composition for transdermal administration
The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a wt1 peptide and/or a modified wt1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject..
08/07/14
20140219979
Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (hsp60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for hsp60 and p277 in the treatment or prevention of hepatic disorders.
08/07/14
20140219971
Algal produced malarial transmission blocking vaccines
The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus chlamydomonas, e.g., chlamydomonas reinhardtii; the immunogenic plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic plasmodium polypeptides produced in an algal host cell.. .
08/07/14
20140216060
Thermo-electric heat pump systems
The invention is directed to an energy efficient thermoelectric heat pump assembly. The thermoelectric heat pump assembly preferably comprises two to nine thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly.
07/31/14
20140212922
Two plasmid mammalian expression system
Reverse engineering has offered new ways of studying the pathology of rna viral infections, new more efficient devices of synthesizing recombinant viruses and developing vaccines and also demonstrated the versatility and efficiency of rna dependent rna polymerase rdrp system as an expression system. However, the currently used methods require a repertoire of complex, difficult-to-use tools.
07/31/14
20140212458
Novel hiv-1 envelope glycoprotein
The present application relates to novel hiv-1 envelope glycoproteins, which may be utilized as hiv-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention..
07/31/14
20140212454
Prevention of salmonella recrudescense
The present invention relates to novel salmonella mutants, to a process for producing the same and to vaccines containing the same, wherein said salmonella mutants are characterized in that they are not responsive to stress-related recrudescence. It is accordingly an object of the present invention to provide the use of said salmonella mutants in the vaccination of animals, in particular mammals and birds, more in particular pigs, poultry and cattle..
07/31/14
20140212452
Vaccination of animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission
Two antigenic and immunogenic proteins of the cattle tick, rhipicephalus microplus, and the genes encoding these proteins, are effective for eliciting a protective immune response that controls and prevents infestations of bovines and other livestock by the tick. The proteins isolated from the cattle tick include an aquaporin protein and a tc5777 gut membrane protein.
07/31/14
20140212451
Lyme disease vaccine
Antigenic polypeptides comprising linear immunodominant epitopes of borrelia outer surface protein a (ospa) or borrelia outer surface protein c (ospc) are useful as vaccines against lyme disease, and as diagnostics for detecting borrelia infections. The ospa and ospc antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups.
07/31/14
20140212450
Protein-based streptococcus pneumoniae vaccines
Vaccine compositions and methods for protecting a mammalian subject against infection with s. Pneumoniae are disclosed.
07/31/14
20140212449
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
A small number of defined antigens can provide broad protection against meningococcal infection, and the invention provides a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or three of hypervirulent lineages a4, et 5 and lineage 3 of n. Meningitidis serogroup b.
07/31/14
20140212447
Rift valley fever virus glycoproteins, gn and gc, and their use
The present invention describes subunit vaccines containing gn and gc glycoproteins of the rift valley fever virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits.. .
07/31/14
20140212434
Multivalent vaccines for rabies virus and filoviruses
The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector omprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compostions comprising the vaccine vectors..
07/24/14
20140206556
Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.. .
07/24/14
20140206062
Recombinant influenza viruses for vaccines and gene therapy
The invention provides compositions and methods useful to prepare segmented, negative strand rna viruses, e.g., orthomyxoviruses such as influenza a viruses, entirely from cloned cdnas and in the absence of helper virus.. .
07/24/14
20140205993
Recombinant avian influenza vaccine and uses thereof
The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a subunit vaccine based on the hemagglutinin of influenza.
07/24/14
20140205656
Modified cationic liposome adjuvants
The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the igg sub-type response and enhancing the cd8 response of the liposomal adjuvant. This technology can be used to increase the production of igg2 antibodies.
07/24/14
20140205652
Novel method and compositions
The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants..
07/24/14
20140205633
Immunostimulatory oligodeoxynucleotides
The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease, to methods for the detection of such oligodeoxynucleotides and to cells to be used in these method.. .
07/24/14
20140205624
Tetravalent and mixed head bivalent dengue vaccine
The present invention relates to immunogenic compositions and vaccines of flavivirus. In particular, the present invention relates to improved dengue vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine.
07/24/14
20140205623
Protein-based streptococcus pneumoniae vaccines
Vaccine compositions and methods for protecting a mammalian subject against infection with s. Pneumoniae are disclosed.
07/24/14
20140205622
Vaccines against influenza virus
Were m2e is the influenza m2 ectodomain (m2e) peptide; cys is a cysteine amino acid residue present in the m2e peptide; s the sulfur present in the cysteine amino acid residue; ch2-co—nh—ch2-ch2-co the linking group; nh the amine group present in a lysine residue of the carrier; lys is a lysine amino acid residue and pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza ha protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza ha protein has been modified to remove an n-terminal leader amino acid sequence and a c-terminal transmembrane domain.
07/24/14
20140205620
Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines
Highly antigenic yet safe vaccines against diseases caused by paramyxoviridae viruses such as respiratory syncytial virus (rsv) are provided. The vaccines comprise attenuated paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (m) protein.
07/24/14
20140205619
Recombinant avian influenza vaccine and uses thereof
The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a subunit vaccine based on the hemagglutinin of influenza.
07/24/14
20140205538
Vaccines targeting cellular death receptors
The invention provides therapeutics and methods to induce a mammalian host, including a human, to produce antibodies, which agonize death receptors and cause the apoptotic death of target cells within the host's body. The therapeutics are vaccine compositions, including genetic vaccines encoding death receptor antigens of the tumor necrosis factor receptor family.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2822

3688

1 - 1 - 81